



For further information:
Marta Campos Martínez
mcampos@rovi.es
Tel: +34 91 244 44 22

ROVI achieves second place in a worldwide sustainability rating

Madrid, Spain - 9th August 2021 – ROVI's ESG aspects have been evaluated by Sustainalytics, a Global Leader in ESG & Corporate Governance, obtaining an "ESG Risk Rating 2020" of 18.4, which places the company at low risk (between 10 and 20). This rating is 3.4 points higher than the previous year's rating (21.8), when the company reached a medium risk position (between 20 and 30 points).

ROVI attains the second position out of 432 companies in the sub-industry "pharmaceuticals" and 17th out of a total of 896 companies in the "pharmaceutical industry", which includes biotech, pharmaceutical and laboratory equipment companies.

You can see ROVI's evaluation at this link:

<https://www.rovi.es/en/relaciones-con-los-grupos-de-inter%C3%A9s>

About ROVI

ROVI is a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, already marketed in 58 countries all over the world, should be highlighted. Likewise, in 2017, ROVI commenced the marketing of its enoxaparin biosimilar, developed in-house. in Europe. ROVI continues to develop the

ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release, with proven advantages. For more information, please visit www.rovi.es